source
- Novo pays $300 million upfront to license Hengrui’s weekly oral GLP-1/GIP weight-loss drugNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui for a preclinical weekly oral GLP-1/GIP receptor agonist aimed at weight loss. The deal involves an upfront payment of $…
- Midterm elections could reshape drug pricing, Medicaid funding and research support, industry leaders warnThe November midterm elections are set to influence major health-care policy debates in Washington, according to STAT+. Industry leaders say the outcome could affect Medicaid funding levels, the p…